Advanced search
Publication Cover
Patient Preference and Adherence Volume 4, 2010 - Issue
Submit an article Journal homepage
57
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study

William Camu1 MS Clinic, CHU Gui de Chauliac, University of Montpellier I, Montpellier, FranceCorrespondence[email protected]
,
Karim Hadjout2 Department of Neurology, Centre Hospitalier, Rodez, France
,
Sabine Latour3 Merck Serono S.A. – Geneva, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany
,
Dieter Pöhlau4 Multiple Sclerosis Center, Kamillus-Klinik Asbach, Asbach, Germany
&
Said Masri5 Praxis Masri, Berlin, Germany
Pages 127-133 | Published online: 06 May 2010

References

  • KapposLTraboulseeAConstantinescuCLong-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSNeurology200667694495317000959
  • PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group; and the University of British Columbia MS/MRI Analysis GroupPRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS [published correction appears in Neurology. 2001;25;57(6):1146]Neurology200156121628163611425926
  • PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupRandomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis [published correction appears in Lancet. 1999;353(9153):678]Lancet19983529139149815049820297
  • GiovannoniGBarbarashOCasset-SemanazFSafety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week resultsMult Scler200915221922818755819
  • MikolDDBarkhofFChangPComparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialLancet Neurol200871090391418789766
  • PanitchHGoodinDSFrancisGEVidence of Interferon Dose-response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE TrialNeurology200259101496150612451188
  • JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis The Multiple Sclerosis Collaborative Research Group (MSCRG) [published correction appears in Ann Neurol 1996;40(3):480]Ann Neurol19963932852948602746
  • The IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trialNeurology19934346556618469318
  • BayasARieckmannPManaging the adverse effects of interferon-beta therapy in multiple sclerosisDrug Saf200022214915910672896
  • RíoJNosCBonaventuraICorticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trialNeurology200463352552815304586
  • CramerJACuffelBJDivanVAl-SabbaghAGlassmanMPatient satisfaction with an injection device for multiple sclerosis treatmentActa Neurol Scand2006113315616216441244
  • KazisLEAndersonJJMeenanRFEffect sizes for interpreting changes in health statusMed Care1989273 SupplS178S1892646488

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.